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 Abstract 
 Background/Aim: The aim of this study was to examine the discriminatory power of quan-
titative EEG (qEEG) applying the statistical pattern recognition (SPR) method to separate
Alzheimer’s disease (AD) patients from elderly individuals without dementia and from other 
dementia patients.  Methods: The participants were recruited from 6 Nordic memory clinics: 
372 unselected patients [mean age 71.7 years (SD 8.6), 54% women] and 146 healthy elderly 
individuals [mean age 66.5 years (SD 7.7), 60% women]. After a standardized and compre-
hensive assessment, clinical diagnoses were made according to internationally accepted cri-
teria by at least 2 clinicians. EEGs were recorded in a standardized way and analyzed inde-
pendently of the clinical diagnoses, using the SPR method.  Results: In receiver operating 
characteristic curve analyses, the qEEGs separated AD patients from healthy elderly individ-
uals with an area under the curve (AUC) of 0.90, representing a sensitivity of 84% and a spec-
ificity of 81%. The qEEGs further separated patients with Lewy body dementia or Parkinson’s 
disease dementia from AD patients with an AUC of 0.9, a sensitivity of 85% and a specificity 
of 87%.  Conclusion: qEEG using the SPR method could be a useful tool in dementia diag-
nostic workup.  © 2015 S. Karger AG, Basel 
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 Introduction 
 Dementia is one of the major health challenges worldwide. Due to a large increase in 
older individuals, the number of people suffering from dementia will grow from about 35 
million today to more than 100 million during the next 30 years  [1, 2] . Several brain disorders 
can cause dementia, but in more than half of the cases, Alzheimer’s disease (AD) is the primary 
underlying condition, followed by dementia caused by stroke, Lewy body dementia (LBD) 
and several other forms of neurodegenerative disorders of the frontal or temporal lobes (or 
a combination of both) in the brain. Although no cure exists for any of the degenerative brain 
disorders causing dementia today, it is of great importance to make a correct diagnosis in 
patients with symptoms that may indicate dementia as soon as possible. First and foremost, 
several studies have indicated that up to half of the patients referred for dementia evaluation 
do not have dementia but may suffer from other, potentially reversible conditions – depression 
being the most frequently encountered  [3] . Moreover, symptomatic drug treatment exists for 
AD, LBD and Parkinson’s disease dementia (PDD) and should be offered to patients together 
with proper care planning, including support to both patients and family caregivers throughout 
the progression of the disease.
 To diagnose a dementia disorder, clinical criteria are applied based on findings from 
comprehensive clinical assessments. However, most of these clinical criteria are not very 
helpful when patients seek health care services in a very early phase of a dementia disorder 
 [4] . Thus, there is a need for sensitive and precise diagnostic tools that can detect brain 
disorders that will eventually lead to dementia. New specific research criteria for AD have 
been proposed, in which biomarkers have a central role  [5–8] . The use of various MRI tech-
niques, PET and SPECT methods as well as examination of spinal fluid measuring the concen-
trations of β-amyloid and phosphorylated and total tau protein have been shown to be helpful 
in diagnosing AD and to separate AD from other brain disorders causing dementia  [5, 9–12] . 
However, these methods have mainly been used at academic centers. Some of these diag-
nostic tools are very expensive (PET), some are invasive (tapping of spinal fluid), and some 
methods need personnel with high expertise to evaluate the findings (MRI). For these reasons, 
some of the above-mentioned biomarkers cannot be applied in countries with a poor economy, 
and some will not be applied in countries where doctors are reluctant to use invasive methods. 
Thus, there is a need for diagnostic biomarkers that can be applied more widely than PET, 
MRI and spinal fluid markers.
 EEG has the potential for being such a biomarker, as it is cheap, noninvasive and simple 
to use and can be applied outside academic centers. The main EEG abnormalities in AD are 
slowing of alpha activity and increases in theta and delta activities, and these changes corre-
spond well with the severity of AD  [13–15] . Quantitative data from EEG recordings are 
generated by use of computerized analysis  [16] , and quantitative EEG (qEEG) parameters 
have repeatedly shown good discriminatory power between different dementia disorders 
and healthy aging in a number of clinical studies  [17–21] . However, no evidence exists that 
supports a single, most accurate qEEG discriminator for different dementia syndromes and 
disease severity. There is also no agreement on the best classification algorithm based on 
qEEG parameters to be used in a routine diagnostic process for individual patients  [18] .
 A new way to analyze EEG recordings is being developed in Iceland by MentisCura  [22] . 
This method is based on a mathematical model, the statistical pattern recognition (SPR) 
method. It is an advanced model that aims to recognize and classify new data from EEG 
recordings based on comparison with normative data from well-defined patients with various 
dementia disorders and from healthy controls. An Icelandic databank used for the SPR method 
contains EEG recordings from more than 1,000 patients with various dementia diagnoses and 
from about 500 healthy controls. The Icelandic database has been used in order to develop 
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various classifiers contrasting different sub-cohorts. These classifiers can then be applied to 
subsequent EEG recordings, constituting an independent estimate of the properties of the 
classifiers. Only few studies have been published that aimed to validate the SPR method. The 
first pilot study that included a small number of AD patients with dementia of moderate 
degree and normal controls showed that the method had good sensitivity and specificity to 
separate AD patients from healthy controls  [23] . A second Norwegian study, including about 
100 unselected patients referred to a memory clinic, could not replicate the findings from the 
Icelandic pilot study  [24] . However, a later study from Iceland that included a large group of 
patients referred to a memory clinic and normal controls showed very promising results both 
in separating AD patients from normal controls and in separating AD patients from patients 
with other forms of dementia and from those with mild cognitive impairment (MCI)  [25] . 
Thus, conflicting results were reported in different studies that included patients from two 
different memory clinics.
 The aim of the present study was to examine the discriminatory power of qEEG to 
separate patients with AD in a very early phase of the disease from elderly persons without 
dementia, using the SPR method. Subsequently, we wanted to examine if the SPR method 
could be used to differentiate common types of dementia disorder from each other.
 Subjects and Methods 
 Participants 
 The study was conducted by including patients and healthy elderly controls from 6 Nordic memory 
clinics which are members of the Nordic Network in Dementia Diagnostics (NIDD). These memory clinics are 
located at the University Hospitals in Copenhagen and Roskilde (Denmark), at the Deaconess Hospital in 
Bergen and the Oslo University Hospital (Norway), at Karolinska Institutet in Stockholm (Sweden) and at the 
Landspítali National University Hospital in Reykjavik (Iceland). In order to ensure that about 20 patients 
were in each diagnostic group (which is a common requirement for validation studies), each center needed 
to include a minimum of 60 patients and 20 controls. Patients coming for their first assessment were recruited 
randomly, and in most of the clinics, they were included consecutively. However, this was not possible in all 
cases, as only 1 physician per clinic took part in the study. We do not have an overview of how many patients 
declined participation.
 The selection was performed according to the following predefined exclusion criteria: significant neuro-
logical disorder with dementia other than AD, PDD and LBD, major psychiatric disorders and alcohol or drug 
abuse. In all, we included 377 patients. Due to poor quality of the EEG recording, 5 patients were excluded, 
leaving 372 patients for the analyses. The 5 excluded patients did not differ from the included patients with 
regard to any characteristics as shown in  table 1 . The controls were 146 elderly persons; they were recruited 
from among family members of the patients, were employees at the 6 hospitals that participated in the study 
or were recruited by advertising.
 Clinical Diagnostic Assessment 
 All patients were examined according to the standard at each memory clinic, which was similar at all 6 
clinics. Clinical assessment consisted of the following: a history from the patient and an informant, a physical 
examination with the focus on neurological and cardiologic status, blood tests to screen for disorders that 
could be associated with cognitive impairment, neuropsychological tests covering various cognitive domains 
as well as CT or MRI of the brain for the evaluation of white matter changes, general atrophy and atrophy of 
the medial temporal lobes. Lumbar puncture was done for examination of β-amyloid and total tau and phos-
phorylated tau protein in the cerebrospinal fluid when indicated (about half of the patients). Some patients 
were assessed with PET or SPECT. Details of the comprehensive assessment, which was similar in all 6 
memory clinics, can be found in a previously published paper  [26] .
 The clinical diagnoses were made at consensus meetings with all doctors present at the memory clinic, 
or by at least 2 experienced doctors, and they applied the DSM-IV-R and the McKhann criteria for the diag-
nosis of AD, the NINDS-AIREN criteria for vascular dementia, the revised consensus criteria for LBD and the 
Lund-Manchester criteria for frontotemporal dementia  [27–30] . Unspecified dementia and dementia due to 
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PDD as well as depression (major depression was excluded) were diagnosed with the ICD-10 criteria for 
research. The diagnosis of MCI was made using the Winblad criteria, and we subdivided the MCI group into 
amnestic and nonamnestic MCI subgroups  [31] . Patients who did not meet any of the above criteria and had 
normal cognitive test results according to their age were categorized as having subjective cognitive 
impairment (SCI). All diagnoses were made independently of the EEG results (‘blinded’).
 The healthy control persons were interviewed, and histories of previous and present disorders and use 
of drugs were recorded. They were tested with a cognitive test battery (see below) to make sure that they 
had no cognitive impairment. Any individuals with a test result on a cognitive test below 1 SD according to 
their age were excluded. Further examinations were not conducted.
 Additional Information Used in the Analyses 
 For the patients, the results of the following cognitive tests were used: (1) the Mini-Mental State Exam-
ination (MMSE)  [32, 33] (a measure of overall cognitive function consisting of 20 items with a minimum score 
of 0 and a maximum score of 30, with lower scores indicating more severe cognitive impairment); (2) the 
Clock-Drawing Test (CDT)  [34] (a short screening test of cognition and possibly of visuospatial function; we 
used the scoring procedure of Shulman, with a minimum score of 0 and a maximum score of 5, with lower 
scores indicating poorer function), and (3) the 10-word tests of the Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD)  [35] , which tested the capacity to learn 10 words with 3 repetitions (CERAD-
learning; max. score 30), to recall the 10 words after 10 min (CERAD-recall; max. score 10) and to recognize 
the 10 words among another 10 words (CERAD-recognition; max. score 20). A lower score on each of the 3 
tests indicates poorer cognition. Depression was assessed using a modified version of the Montgomery-
Åsberg Depression Rating Scale (MADRS)  [36] . Each of the 10 items was assessed as present or not, yielding 
a minimum score of 0 and a maximum score of 10. A higher score denotes more depressive symptoms.
 The controls were tested with the MMSE, CDT and CERAD 10-word tests (all 3 parts), and depression 
was rated with the modified MADRS in the same way as were the patients. Demographic variables such as 
age, gender, marital status and years of schooling as well as use of drugs and comorbidities were recorded 
for both the patients and the controls.
Control vs. clinical AD vs. clinical  DLB/PDD vs. clinical
coherence feature coherence feature cohe rence feature
Fp2/P4 TP Fp1/P3 γ Fp1/O1 β1
C4/O2 θ F3/O1 α2 Fp2/O2 δ
F7/F8 TP F4/O2 δ Fp1/P3 PAF
T3/T4 γ F4/O2 θ Fp2/P4 β2
T3/T4 PAF F3/P3 θ F3/O1 α2
T5/T6 α1 F4/P4 δ F3/F4 PAF
P3/P4 β1 C3/O1 θ T5/T6 α1
O1/O2 TP C3/O1 TP O1/O2 θ
Fp1/F7 α2 C3/O 1 PAF Fp1/F3 θ
Fp2/F8 α1 F7/F8 PAF Fp1/F3 TP
Fp2/F8 γ T5/T6 α2 Fp2/F4 TP
Fp2/F8 TP Fp1/F7 PAF F7/C3 β1
Fp1/F3 β1 Fp2/F8 PAF F3/C3 PAF
F8/C4 θ Fp1/F3 θ F4/C4 PAF
F3/C3 PAF Fp1/F3 PAF P3/O1 δ
P3/O1 δ F7/T3 β2 C3/T5 θ
P4/O2 γ T6/O2 θ C3/T5 γ
C4/T6 α1 C4/T6 α1 C4/T6 α1
C4/T6 TP P3/C3 θ P3/C3 β2
P4/C4 δ P4/T6 α1 P4/T6 α1
PAF = Peak alpha frequency; TP = total power.
 Table 1.  Features that were used 
to create the healthy control 
index, the AD index and the DLB/
PDD index
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 EEG Recordings and Evaluation 
 EEGs were recorded using NicoletOne EEG Systems (Natus ® ). Subsequent analysis was done in the 
MATLAB environment (MathWorks ® ). The IS 10-20 system was used for electrode placement (with 19 elec-
trodes), and the features were evaluated using the average montage. Two bipolar electro-oculography 
channels and 1 electrocardiogram were applied to monitor artifacts. The EEGs were recorded for at least 3 
min, with the subjects at rest with their eyes closed. They were alerted if they became visibly drowsy, since 
drowsiness influences recording.
 qEEG Feature Extraction 
 For each EEG channel, 20 spectral features were extracted; coherence was estimated for 37 chosen 
channel pairs, and the same spectral features were extracted as for each individual channel. Thus, a total of 
1,120 features were extracted from each EEG recording. The reliability of the EEG features used in this study 
has already been investigated and described  [22] .
 qEEG Resampling 
 The EEGs gathered in the present study were sampled at 1,024, 1,000, 512, 500, 256, 250 or 200 Hz in 
the 6 partaking centers. All EEGs in this study were resampled to 256 Hz in order to make them comparable. 
In cases were the original sampling was higher than 256 Hz, the samples were downsampled by averaging. 
If the sampling frequency was 200 Hz, the samples were upsampled by linear bridging between all adjacent 
points and then sampled at 256 Hz.
 qEEG Classifiers 
 The data are analyzed applying the SPR technique, which is used to construct a classifier from two diag-
nostic groups of qEEGs, for example, qEEGs from a group A and a group B  [23, 25] . When an EEG is classified, 
the classifier returns an index, the A-B index, with a value between 0 and 1. If the A-B index is close to 0, the 
EEG is indistinguishable from the EEGs in group A, and if the A-B index is close to 1, the EEG is indistin-
guishable from the EEGs in group B. In order to minimize the risk of overfitting, each classifier is restricted 
to rely only on a set of 20 qEEG features out of the 1,120 features available. For each classifier construction 
there are thus 3 × 10 42 distinct possibilities. Hence, a genetic algorithm was applied to select the features 
used in the construction of the classifier for each pair of groups  [37] . The target value for the genetic evolu-
tion of classifiers was the area under the curve (AUC) of the corresponding receiver operating character-
istic (ROC) curve. The objective was not to find the best classifier in each case – which is a near impossible 
task – but rather to find a classifier with clinically acceptable qualities.
 Three classifiers derived from the data gathered in a previous study  [25] were used in the analysis of 
the qEEG data of the present study. The first one, the ‘healthy control index’, was constructed to separate a 
qEEG derived from a healthy individual from that derived from an individual who suffers from MCI or any 
dementia disorders. The second one, the ‘Alzheimer’s disease index’ (AD index), was constructed to detect 
AD patients and separate them from the clinical cohort with any diagnosis except AD (not controls). The third 
one, the ‘diffuse Lewy body/Parkinson’s disease index’ (DLB/PDD index), was constructed to detect patients 
with LBD or PDD among the clinical cohort and separate them from all other patients in the study (not 
controls). Each of the recordings gathered in this study was classified by the three indices described above. 
The classification in our study is comparable with the previous classification used in qEEG studies conducted 
in Iceland and Norway, which employed the same SPR algorithm. The features used in each of the three 
indices in the present study are shown in  table 1 .
 Statistics 
 All data were analyzed using the SPSS software version 20. Continuous data are presented as means and 
SD. Categorical data are given as numbers and percentages. To test for differences between groups, we used 
the independent t test or one-way ANOVA (more than 2 groups) for continuous data and the χ 2 test for cate-
gorical data. Lastly, we performed ROC analyses to examine the discriminatory power of the indices to 
separate AD patients from normal elderly individuals and to examine whether qEEG could be used to separate 
patients with various dementia disorders from each other. The results of the ROC analyzes are given as AUC, 
sensitivity, specificity, likelihood ratio for a positive test (LR+) and likelihood ratio for a negative test (LR–). 
The AUC should be significantly larger than 0.5 if the test (EEG) is better than what is achieved at random. 
The following formulas for LR+ and LR– were used: LR+ = probability of a positive result in a person with a 
disease/probability of a positive results in a person without the disease (true positive/false positive) = sensi-
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tivity/1 – specificity; LR– = probability of a negative result in a person with a disease/probability of a negative 
results in a person without the disease (false negative/true negative) = 1 – sensitivity/specificity.
 Ethical Considerations 
 In this study, we included healthy elderly individuals and patients with MCI or dementia at a very early 
stage. Thus, only persons with the capacity to consent to participation were included. All participants were 
given oral and written information, and they consented to participation in writing. The study was approved 
by the ethics committees in each of the 4 countries.
 Results 
 The characteristics of the patients and the controls are shown in  table 2 . Except for 
education, no other demographic variable differed significantly between the two groups. The 
mean age of the female patients was 72.4 years (SD 9.2), and that of the men 71.0 years (SD 
7.9; p = 0.12). The mean age of the female controls was 66.1 years (SD 7.8), and among the 
men it was 67.1 years (SD 7.2; p = 0.48). Comorbidities were more often observed in the 
patient sample than in the control sample, as was the use of psychotropic drugs that could 
possibly interfere with the EEG measurements. It should be noted that only 23 patients used 
anti-dementia drugs (first assessment at a memory clinic). Of the 10 individuals who used 
Patients
(n = 372)
Controls
(n = 146)
Demographics
Mean age ± SD, years 71.7 ± 8.6 66.5 ± 7.7
Female gender, n (%) 200 (54) 87 (60)
Married, n (%) 245 (66) 106 (74)
Education >9 years, n (%) 240 (65) 124 (85)
Primary clinical diagnosis-related dementia assessment, n (%)
Healthy controls 146 (100)
Depression 12 (3)
SCI 63 (17)
MCI 121 (33)
AD 135 (36)
Vascular dementia 15 (4)
LBDa 15 (4)
Other dementiasb 10 (3)
Other comorbid diagnosis, n (%)
Any heart disease 76 (20) 6 (4)
Diabetes 40 (11) 8 (6)
Previous stroke 20 (5) 1 (<1)
Previous or present depression 91 (24) 4 (3)
Use of drugs, n (%)
Antipsychotics 9 (2) 1 (1)
Antidepressants 71 (19) 3 (2)
Tranquilizer/hypnotics 27 (7) 3 (2)
Anti-dementia drugsc 23 (6) 0
Pain killers 17 (5) 4 (3)
 a 10 with LBD and 5 with PDD.
b 4 with frontal lobe dementia and 6 with dementias not specified.
c 1 with memantine, otherwise acetylcholinesterase inhibitors.
 Table 2. Characteristics of the 
participants included in the 
analyses
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antipsychotics, 5 had dementia. With regard to antidepressants, the majority (n = 46) of the 
76 patients who used this group of medication were not demented; 23 had AD.
 The healthy controls and the patients with an SCI diagnosis performed similar on all 
cognitive tests, and these two groups did not differ statistically on any test results ( table 3 ). 
The 12 patients with a primary diagnosis of depression had a cognitive function similar to 
that of the MCI patients. However, the amnestic MCI group (n = 57) differed from the nonam-
nestic group (n = 67) with regard to cognitive test results [mean MMSE 26.1 (SD 2.1) and 
10-word CERAD-recall 1.6 (SD 1.2) vs. mean MMSE 28.0 (SD 1.7) and 10-word CERAD-recall 
5.5 (SD 1.4); p < 0.001 for both measurements]. Otherwise, we found a significant decrease 
in test performance on all tests on the axis ‘healthy controls/SCI-MCI/depression-dementia’ 
(one-way ANOVA, p < 0.001 for all tests).
 The mean depression score (maximum 10) among the patients was 1.97 (SD 2.1), 
compared to 0.1 (SD 0.5) among the controls (p < 0.001). In the clinical sample, the highest 
 Table 3. Cognitive performance of the participants
Clinical diagnosis MMSE CDT CERAD-learning CERAD-recall CERAD-recognition
None (controls) 28.9 (1.3) 4.8 (0.5) 20.4 (4.0) 7.3 (1.7) 20 (1.4)
Depression 27.0 (4.0) 4.0 (1.6) 14.8 (5.8) 4.3 (2.5) 17.2 (2.7)
SCI 28.7 (1.3) 4.8 (0.5) 20.0 (3.9) 6.6 (2.3) 20.0 (1.5)
MCI 27.1 (2.1) 4.4 (1.0) 15.2 (4.3) 3.6 (2.3) 18.0 (2.0)
AD 23.3 (3.4) 3.7 (1.4) 11.0 (3.7) 1.5 (1.6) 15.8 (2.6)
Vascular dementia 22.7 (4.0) 3.3 (1.5) 11.6 (3.7) 1.9 (1.7) 16.3 (2.5)
LBD/PDD 24.1 (2.8) 2.8 (1.6) 11.5 (4.8) 3.4 (2.0) 17.4 (2.3)
Other dementias 24.3 (3.4) 3.6 (1.4) 12.2 (6.4) 2.7 (2.7) 18.0 (1.7)
Values are presented as means (SD).
Clinical 
diagnosis
Healthy
control index
AD
index
DLB/PDD
index
None (controls) 0.70 (0.22) 0.66 (0.24) 0.10 (0.12)
Depression 0.46 (0.28) 0.52 (0.30) 0.16 (0.23)
SCI 0.60 (0.25) 0.61 (0.23) 0.13 (0.13)
MCI 0.46 (0.28) 0.73 (0.25) 0.14 (0.15)
AD 0.24 (0.24) 0.70 (0.20) 0.24 (0.24)
Vascular dementia 0.22 (0.30) 0.77 (0.21) 0.19 (0.19)
LBD/PDD 0.07 (0.10) 0.39 (0.25) 0.77 (0.25)
Other dementias 0.32 (0.28) 0.74 (0.24) 0.21 (0.20)
The probabilities are given as means (SD). A value close to 1 indicates 
that the qEEG index can detect patients with a certain clinical diagnosis. 
The healthy control index is based on EEGs from healthy controls vs. 
patients with dementia, depression or substance abuse as derived from 
the database in Iceland by MentisCura. The AD index is based on EEGs 
from patients with AD vs. patients with all other dementia disorders. 
The DLB/PDD index is based on EEGs from patients with LBD/PDD vs. 
those with other dementias.
 Table 4. The crude probabilities 
of belonging to the group of 
normal healthy elderly individuals 
or the various clinical diagnostic 
groups by qEEG based on the SPR 
method, using the three indices
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depression score was found among those with a diagnosis of depression [4.4 (SD 2.1)], 
followed by those patients with a diagnosis of LBD/PDD [3.1 (SD 1.8)] and SCI [2.5 (SD 2.4)]. 
The lowest score was found among the AD patients [1.4 (SD 1.9); one-way ANOVA, p = 0.006].
 In  table 4 we present the crude qEEG results, e.g. the probabilities for the controls and each 
of the clinical diagnostic groups of belonging to the healthy control group, the AD group or the 
group of patients suffering from either DLB or PDD based on the SPR method. The 10 patients 
with LBD did not differ from the 5 patients with PDD (data not shown), and we therefore treated 
them as one group to have more subjects in this group, which has been done in several studies. 
The amnestic MCI group did not differ from the nonamnestic MCI group on any of the three 
indices, and we therefore did not make separate analyses for the two MCI groups in the further 
analyses. The 15 patients with a diagnosis of LBD or PDD differed markedly and significantly 
(p < 0.001) from the other dementia patients on all three indices ( table 4 ).
 The results of the ROC analyses are shown in  table 5 . Besides reporting the AUCs, we 
added the sensitivity and specificity for situations where the sensitivity should be  ≥ 70%. Two 
of the ROC analyses are shown as ROC curves in  figure 1 to illustrate the main findings.
 Discussion 
 This is the first study of this extent that uses the SPR method to analyze qEEGs for the 
differential diagnosis of individual patients with a user-friendly composite score extracted 
from multiple qEEG features. By including patients recruited from everyday clinical practice 
at 6 Nordic memory clinics, we found that qEEG, using the SPR method, was very useful in 
separating patients with LBD or PDD from all other clinical patients regardless of their 
cognitive status and diagnosis. We further found that the EEG method separated patients with 
AD from normal controls but did not separate patients with AD from those with other dementia 
disorders, except for DLB/PDD. The method poorly separated patients with AD from those 
with MCI, which could be expected, as a proportion of individuals with MCI are in fact in an 
early stage of AD.
 Table 5. ROC analyses
Group comparisons AUC (95% CI) Sensitivity Specificity LR+ LR–
Healthy control index
Healthy controls vs. all clinical patients 0.80 (0.76 – 0.84) 0.77 0.77 3.3 0.30
Healthy controls + SCI vs. all other patients 0.82 (0.78 – 0.85) 0.75 0.75 3.0 0.33
Healthy controls vs. AD patients 0.90 (0.86 – 0.94) 0.84 0.81 4.4 0.20
AD index
AD patients vs. controls 0.54 (0.47 – 0.61) NA NA NA NA
AD patients <65 years vs. controls 0.69 (0.54 – 0.83) 0.70 0.65 2.0 0.46
AD patients vs. all other clinical patients 0.58 (0.53 – 0.65) 0.70 0.40 1.7 0.75
AD patients vs. other patients with dementia 0.57 (0.46 – 0.68) NA NA NA NA
DLB/PDD index
DLB/PDD patients vs. controls 0.99 (0.97 – 1.00) 0.95 0.93 13.6 0.05
DLB/PDD patients vs. all clinical patients 0.95 (0.91 – 0.99) 0.87 0.87 6.7 0.15
DLB/PDD patients vs. other dementia patients 0.92 (0.86 – 0.98) 0.86 0.87 6.6 0.16
DLB/PDD patients vs. AD patients 0.92 (0.86 – 0.98) 0.85 0.87 6.5 0.17
NA = Not appropriate to calculate, as AUC does not differ from 0.5 (chance).
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 In the ROC analyses, the SPR method using the DLB/PDD index distinctly separated the 
DLB/PDD patients from the AD patients, the other patients with and without dementia and 
the controls. AUCs >0.9, a high sensitivity, specificity and LR+ as well as a low LR– all indicate 
that the method is valid. The study by Snaedal et al.  [25] from the Memory Clinic in Iceland 
reported similar results, but no information on the cognitive status of the patients was given. 
In the present study, the DLB/PDD patients were in the stage of early dementia, with MMSE 
scores of 24.1 ± 2.8 points. Other studies support our findings that the qEEG characteristics 
of DLB/PDD patients differ from those of patients with other dementias  [19, 38, 39] . The most 
probable reason for this convincing result is that qEEG using the SPR method captures the 
specific EEG pattern of LBD and PDD. It would be of interest to know if this typical EEG pattern 
is also present in the preclinical stage of LBD. The present study cannot answer this question. 
However, a recently published follow-up study of MCI patients showed that qEEG was able to 
predict the development of LBD  [39] .
 Using the healthy control index – which is based on qEEGs from healthy controls versus 
patients with dementia, depression or substance abuse from the Icelandic database – the SPR 
method well separated the controls from the patient groups and the specific group with a 
diagnosis of AD. The study by Snaedal et al.  [25] came to the same conclusion, but with statis-
tically better results. The results can be seen as a ‘proof of concept’ of the SPR method and 
may indicate that this method, measuring the electrophysiology of the brain, can be used in 
order to increase diagnostic certainty when diagnosing the causes of dementia.
 Using the AD index, which is based on EEGs from patients with AD versus those with all 
other dementia disorders, the SPR method did not significantly separate AD patients from 
other patients with dementia. Younger AD patients were separated from normal controls and 
from other younger clinical patients in a significant way, although the discriminatory power 
was not perfect, as expressed by the low AUC and LR+ and the high LR–. These results are in 
accordance with those of a previous study by Ommundsen et al.  [24] , which also included an 
unselected group of memory clinic patients. This result might be seen as beneficial, since 
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 Fig. 1.  a ROC analysis of qEEG using the healthy control index to separate controls from AD patients.  b ROC 
analysis of qEEG using the DLB/PDD index to separate DLB/PDD patients from other demented patients. 
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younger patients with AD more often have atypical clinical presentations and are generally 
much harder to diagnose than older patients with AD.
 This study can be compared with the study by Ommundsen et al.  [24] , as both used the 
EEG SPR method in the same way to evaluate individual EEG registrations on the basis of a 
database that had been formed earlier, not including any of the same cases. The study by 
Snaedal et al.  [25] used the method in a different way, i.e. to separate several clinical groups 
and controls, thereby creating a database on the basis of their difference in EEG features the 
other studies rely on. This could be the main reason for the more favorable results of that 
study.
 Use of psychotropic drugs and comorbid disorders, especially brain disorders, could 
have influenced the EEG recordings and thereby biased the results. In the present study, less 
than half of the patients used such drugs, and less than half of them had comorbid disorders. 
The EEG recordings could therefore have been influenced only to some degree. However, our 
sample represents patients who typically are referred to a memory clinic, and we have to 
take into consideration that these patients could have comorbid disorders that possibly 
influence all the examinations that are applied in a dementia workup. In this study, we 
wanted to test the value of qEEG among typical memory clinic patients, not a sample of 
selected patients.
 The study has limitations. Although at least 2 experienced physicians made the clinical 
diagnoses at each center, we cannot rule out that some patients had been falsely diagnosed. 
Most patients with dementia were in an early stage of disease, and diagnoses at this stage can 
be difficult to make. This is also the case for the distinction between dementia and MCI, where 
only a follow-up of the patients could reveal progression to dementia. Secondly, we did not 
use all biomarkers that are available today in all patients, only as indicated according to 
routine clinical practice. Some patients may have received a false diagnosis for this reason. 
The strengths of the study are the fairly large number of patients and controls included and 
that the patients were included in an unselected manner, recruited from everyday clinical 
practice. A further strength is that the patients were examined in a standardized manner with 
a harmonized protocol, since it was performed in centers that have been participating in the 
NIDD in recent years, harmonizing their diagnostic workups.
 To sum up, only two studies on qEEG using the SPR method have been published that 
include patients from everyday practice: the present one and the study by Ommundsen et al. 
 [24] . Using clinical diagnoses as the gold standard, our study showed that the SPR method 
was excellent in discriminating DLB/PDD patients from both healthy controls and patients 
with other dementia disorders but poor in discriminating between AD patients and patients 
with other clinical diagnoses. The method well separated normal controls from those with 
dementia, including AD. Other previously reported studies on the use of this method showed 
more favorable results, but they had been conducted using the SPR method to separate 
groups, not to examine individuals  [23, 25] .
 Further longitudinal studies of MCI patients followed up clinically in the same stan-
dardized way as within the NIDD should be conducted to examine if this qEEG method could 
separate patients with LBD from AD patients in a preclinical phase – as has been done in a 
recent Italian study  [39] . Furthermore, the method should be compared to other biomarkers 
of degenerative disorders of the brain, first and foremost AD, as the current project indicates 
that EEG could add to the diagnostic arsenal in cognitive impairment and dementia. The 
method is cheap, noninvasive and simple to use and can be applied outside academic centers; 
also, there is a need for diagnostic methods that can be applied more widely than PET, MRI 
and spinal fluid marker assessment.
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